彭鑫，助理教授、博士生導(dǎo)師、研究員。2015年獲得天津醫(yī)科大學(xué)學(xué)士學(xué)位，2020年獲得天津醫(yī)科大學(xué)博士學(xué)位（2019年至2020年，先后作為MD安德森癌癥中心系統(tǒng)生物學(xué)系及生物信息學(xué)系聯(lián)培博士）。獲得天津市自然科學(xué)二等獎(jiǎng)，天津市“海河英才”創(chuàng)新創(chuàng)業(yè)大賽博士后揭榜領(lǐng)題賽銅獎(jiǎng)。入選中國(guó)科協(xié)“青年人才托舉工程”項(xiàng)目。主持6項(xiàng)國(guó)家級(jí)及省部級(jí)科研課題。 院校引進(jìn)人才，2024年加入院校。曾于2021年至2024年在天津醫(yī)科大學(xué)任博士后；2020年至2021年在MD安德森癌癥中心任博士后。

長(zhǎng)期從事以基于多組學(xué)數(shù)據(jù)挖掘結(jié)合實(shí)驗(yàn)篩選平臺(tái)，進(jìn)行腫瘤新藥研發(fā)與精準(zhǔn)治療研究。涉及抗腫瘤藥物靶點(diǎn)發(fā)現(xiàn)及合成、DNA損傷療法增敏生物標(biāo)志物篩選及聯(lián)用策略開發(fā)等關(guān)鍵科學(xué)問題。作為核心研究人員開發(fā)的新型pan-PI3K抑制劑KTC1101在MedChemExpress公司商業(yè)化轉(zhuǎn)化。發(fā)表SCI論文18篇，其中第一或通訊作者文章7篇，如Mol Cancer（2篇），Signal Transduct Target Ther，Adv Sci（2篇），Cancer Res，J Exp Clin Cancer Res等，合作文章發(fā)表在Cancer Cell等期刊。他引次數(shù)588，單篇最高他引次數(shù)158，H指數(shù)16。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1. Xin Peng#*, Yingying Wang#, Zixiang Yu#, Shaolu Zhang, Zhenxing Zhong, Yongzhe Wang, Shanshan Liu, Kailin Wang, Christophe Nicot*, Francois X. Claret*, Dexin Kong*. Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer. Mol Cancer. 2025, 24(1):217. (IF=33.9)

2. Xin Peng#, Xin Huang#, Talal Ben Lulu#, Wenqing Jia, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Xi Chen, Shanshan Liu, Yongzhe Wang, Kailin Wang, Sho Isoyama, Shingo Dan, Feng Wang, Zhe Zhang*, Moshe Elkabets*, Dexin Kong*. A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation. Mol Cancer. 2024, 23(1):54. (IF=41.4)

3. Xin Peng#, Xin Huang#, Shaolu Zhang#, Naixin Zhang, Yingying Wang, Zixiang Yu, Xi Chen, Moshe Elkabets, Francois X. Claret, Feng Wang, Ning Ji*, Yuxu Zhong*, Dexin Kong*. Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma. Adv Sci. 2024, 11(30):2307747. (IF=14.1)

4. Xin Peng#, Yingying Wang#, Shaolu Zhang#, Zhennan Tao, Yuxiang Dai, Francois X. Claret, Moshe Elkabets, Hou-Wen Lin*, Zhe-Sheng Chen*, Dexin Kong*. Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homologous recombination repair. Signal Transduct Target Ther. 2023, 8(1):119. (IF=38.104)

5. Xin Peng, Shaolu Zhang, Yingying Wang, Zhicheng Zhou, Zixiang Yu, Zhenxing Zhong, Liang Zhang, Zhe-Sheng Chen, Francois X. Claret, Moshe Elkabets, Feng Wang, Fan Sun, Ran Wang*, Han Liang*, Hou-Wen Lin*, Dexin Kong*. Stellettin B sensitizes glioblastoma to DNA-damaging treatments by suppressing PI3K-mediated homologous recombination repair. Adv Sci. 2023, 10(3):2205529. (IF=17.521)

6. Xin Peng#, Shaolu Zhang#, Wenhui Jiao, Zhenxing Zhong, Yuqi Yang, Francois X. Claret, Moshe Elkabets, Feng Wang, Ran Wang*, Yuxu Zhong*, Zhe-Sheng Chen*, Dexin Kong*. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. J Exp Clin Cancer Res. 2021, 40(1):374. (IF=11.663)

7. Shaolu Zhang#, Xin Peng#, Xiaofei Li, Hongyan Liu, Baoquan Zhao, Moshe Elkabets, Yao Liu, Wei Wang, Ran Wang*, Yuxu Zhong*, Dexin Kong*. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death Dis. 2021, 12(6):546. (IF=9.685)